DelveInsight’s “Congenital Hyperinsulinism Pipeline Insight 2026” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in the Congenital Hyperinsulinism pipeline landscape. It covers the Congenital Hyperinsulinism pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Congenital Hyperinsulinism pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Congenital Hyperinsulinism Pipeline? @ https://www.delveinsight.com/sample-request/congenital-hyperinsulinism-pipeline-insight

Key Takeaways from the Congenital Hyperinsulinism Pipeline Report

• In May 2026- Hanmi Pharmaceutical Company Limited initiated a phase 2 study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of HM15136 when used as add-on therapy in subjects with CHI with persistent hypoglycemia while on standard of care treatment (SoC). HM15136 will be administered once weekly in multiple doses to subjects in multiple age including pediatric to find appropriate exposure-response data.
• In April 2026- Regeneron Pharmaceuticals conducted a study is researching an experimental drug called mibavademab. The study is focused on participants with GLD who have been on metreleptin treatment for at least 6 months with no change in dose for the last 3 months.
• DelveInsight’s Congenital Hyperinsulinism Pipeline report depicts a robust space with 4+ active players working to develop 4+ pipeline therapies for Congenital Hyperinsulinism treatment.
• The leading Congenital Hyperinsulinism Companies, such as Rezolute Inc., Hanmi Pharmaceutical and others.
• Promising Congenital Hyperinsulinism Therapies such as HM15136, Dasiglucagon, Glucagon, Sandostatine LP, Avexitide, Lyo avexitide, LIK066 and others

Want to know which companies are leading innovation in Congenital Hyperinsulinism? @ Congenital Hyperinsulinism Clinical Trials Assessment

The Congenital Hyperinsulinism Pipeline Report provides a disease overview, pipeline scenario, and therapeutic assessment of the key pipeline therapies in this domain. The Congenital Hyperinsulinism Pipeline Report also highlights the unmet needs with respect to the Congenital Hyperinsulinism.

Congenital Hyperinsulinism Overview

Congenital hyperinsulinism is a rare genetic disorder characterized by inappropriate and excessive secretion of insulin from pancreatic β-cells, resulting in recurrent episodes of hypoglycemia (low blood glucose), particularly in neonates and infants. Insulin normally regulates blood glucose levels, but in this condition, insulin secretion occurs even when glucose levels are low, leading to persistent hypoglycemia that can cause severe neurological complications such as seizures, brain damage, or coma if untreated. The condition shows wide clinical variability, ranging from mild to severe forms, and may present shortly after birth or during early childhood.

Congenital Hyperinsulinism Emerging Drugs Profile

• Ersodetug: Rezolute

Ersodetug (RZ358), developed by Rezolute, is an investigational fully human monoclonal antibody designed to treat hypoglycemia caused by hyperinsulinism, including Congenital Hyperinsulinism. The drug works through a novel mechanism of action by binding to the insulin receptor and reducing excessive insulin signaling, thereby counteracting the effects of abnormally high insulin levels rather than suppressing insulin secretion itself. It is being developed primarily for hypoglycemia due to congenital hyperinsulinism and other forms of hyperinsulinism, addressing a significant unmet medical need in rare diseases. Ersodetug has received multiple regulatory designations, including FDA Breakthrough Therapy Designation for congenital hyperinsulinism, as well as additional designations such as PRIME (EMA) and ILAP Innovation Passport (UK), reflecting its potential clinical benefit. The drug has advanced into Phase III clinical trials (sunRIZE study) for congenital hyperinsulinism.

If you’re tracking ongoing Congenital Hyperinsulinism Clinical trials, this press release is a must-read @ Congenital Hyperinsulinism Treatment Drugs

The Congenital Hyperinsulinism Pipeline report provides insights into:-

• The report provides detailed insights about companies that are developing therapies for the treatment of Congenital Hyperinsulinism with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Congenital Hyperinsulinism Treatment.
• Congenital Hyperinsulinism Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Congenital Hyperinsulinism Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Congenital Hyperinsulinism market.

Congenital Hyperinsulinism Companies

Rezolute Inc., Hanmi Pharmaceutical and others.

Congenital Hyperinsulinism pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Congenital Hyperinsulinism Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

From emerging drug candidates to competitive intelligence, the Congenital Hyperinsulinism Pipeline Report @ Congenital Hyperinsulinism Market Drivers and Barriers, and Future Perspectives

Scope of the Congenital Hyperinsulinism Pipeline Report

• Coverage- Global
• Congenital Hyperinsulinism Companies- Rezolute Inc., Hanmi Pharmaceutical and others.
• Congenital Hyperinsulinism Therapies- HM15136, Dasiglucagon, Glucagon, Sandostatine LP, Avexitide, Lyo avexitide, LIK066 and others.
• Congenital Hyperinsulinism Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Congenital Hyperinsulinism Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Discover what’s next for the Congenital Hyperinsulinism Treatment landscape in this detailed analysis @ Congenital Hyperinsulinism Emerging Drugs and Major Players

Table of Contents

1. Introduction
2. Executive Summary
3. Congenital Hyperinsulinism: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Congenital Hyperinsulinism – DelveInsight’s Analytical Perspective
7. In-depth Commercial Assessment
8. Congenital Hyperinsulinism Collaboration Deals
9. Mid Stage Products (Phase II)
10. Ersodetug: Rezolute
11. Drug profiles in the detailed report…..
12. Early Stage Products (Phase I)
13. Drug profiles in the detailed report…..
14. Pre-clinical and Discovery Stage Products
15. Drug profiles in the detailed report…..
16. Inactive Products
17. Congenital Hyperinsulinism Key Companies
18. Congenital Hyperinsulinism Key Products
19. Congenital Hyperinsulinism- Unmet Needs
20. Congenital Hyperinsulinism- Market Drivers and Barriers
21. Congenital Hyperinsulinism- Future Perspectives and Conclusion
22. Congenital Hyperinsulinism Analyst Views
23. Congenital Hyperinsulinism Key Companies
24. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/congenital-hyperinsulinism-pipeline-insight